Alternatives to hysterectomy in the management of leiomyomas

Obstetrics and Gynecology

Volumn 112, Issue 2 PART 1, 2008, Pages 387-400

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIGESTAGEN; AROMATASE INHIBITOR; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; LEVONORGESTREL; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; VASOPRESSIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ABDOMINAL SURGERY; ADJUVANT THERAPY; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; BALLOON CATHETER; CESAREAN SECTION; CLINICAL TRIAL; CONTRACEPTION; DRUG COST; DRUG MECHANISM; DRUG MEGADOSE; ECHOGRAPHY; ENDOMETRIUM HYPERPLASIA; FEMALE INFERTILITY; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; INTERVENTIONAL RADIOLOGY; LAPAROSCOPIC SURGERY; LAPAROTOMY; LOW DRUG DOSE; MENOPAUSE; MORBIDITY; MYOMECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PREGNANCY RATE; PREOPERATIVE TREATMENT; PREVALENCE; PRIORITY JOURNAL; REOPERATION; REVIEW; ROBOTICS; SIDE EFFECT; STEROID THERAPY; SURGICAL TECHNIQUE; THERAPY EFFECT; TOURNIQUET; TREATMENT INDICATION; TREATMENT OUTCOME; TRIAL OF LABOR; ULTRASOUND THERAPY; UNSPECIFIED SIDE EFFECT; UTERINE ARTERY EMBOLIZATION; UTERUS BLEEDING; UTERUS MYOMA; UTERUS RUPTURE; VAGINAL HYSTERECTOMY; VASOCONSTRICTION; ARTICLE; ARTIFICIAL EMBOLISM; FEMALE; GYNECOLOGIC SURGERY; LAPAROSCOPY; LEIOMYOMA; ORGAN SIZE; PATHOLOGY; PRACTICE GUIDELINE; UTERUS; UTERUS CANCER; UTILIZATION REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; EMBOLIZATION, THERAPEUTIC; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; HYSTERECTOMY; HYSTEROSCOPY; LAPAROSCOPY; LEIOMYOMA; LEUPROLIDE; MENOPAUSE; ORGAN SIZE; TREATMENT OUTCOME; UTERINE NEOPLASMS; UTERUS;

EID: 51649114074     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318183fbab     Document Type: Review

References (117)

1. Fraser IS, Critchley HO, Munro MG, Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Writing Group for this Menstrual Agreement Process. Fertil Steril 2007;87: 466-76. (Level III)
2. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7. (Level II-3)
3. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003855. DOI: 10.1002/14651858.CD003855.pub2. (Level III)
4. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004;104:393-406. (Level III)
5. Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol 2004;24:798-800. (Level III)
6. Harrison-Woolrych M, Robinson R. Fibroid growth in response to high-dose progestogen. Fertil Steril 1995; 64:191-2. (Level III)
7. Mixson WT, Hammond DO. Response of fibromyomas to a progestin. Am J Obstet Gynecol 1961;82:754-60. (Level III)
8. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-23. (Level II-3)
9. Friedman AJ, Haas ST. Should uterine size be an indication for surgical intervention in women with myomas? Am J Obstet Gynecol 1993;168:751-5. (Level III)
10. Friedman AJ, Daly M, Juneau-Norcross M, Fine C, Rein MS. Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril 1992;58:205-8. (Level III)
11. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-9. (Level II-2)
12. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004;159:113-23. (Level II-2)
13. Mercorio F, De Simone R, Di Spiezio Sardo A, Cerrota G, Bifulco G, Vanacore F, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003; 67:277-80. (Level III)
14. Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol 2004;16:239-43. (Level III)
15. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993;77:324-31. (Level I)
16. Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 2003;79:628-31. (Level III)
17. Attilakos G, Fox R. Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole. J Obstet Gynaecol 2005;25:609-10. (Level III)
18. Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, Makedos GA, Vlassis GD. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol 2007; 110:643-9. (Level III)
19. Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjoblom P, Norgren A, et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 1998;83:4092-6. (Level III)
20. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophinreleasing hormone agonist therapy. Hum Reprod 1999; 14:2844-50. (Level II-3)
21. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006;108: 1381-7. (Level I)
22. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-33. (Level II-2)
23. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-6. (Level III)
24. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-7 (Level III)
25. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101:243-50. (Level I)
26. Hillis SD, Marchbanks PA, Peterson HB. Uterine size and risk of complications among women undergoing abdominal hysterectomy for leiomyomas. Obstet Gynecol 1996;87:539-43. (Level II-2)
27. Iverson RE Jr, Chelmow D, Strohbehn K, Waldman L, Evantash EG. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996;88:415-9. (Level II-2)
28. Ecker JL, Foster JT, Friedman AJ. Abdominal hysterectomy or abdominal myomectomy for symptomatic leiomyoma: a comparison of preoperative demography and postoperative morbidity. J Gynecol Surg 1995;11: 11-7. (Level III)
29. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36:433-45. (Level III)
30. Candiani GB, Fedele L, Parazzini F, Villa L. Risk of recurrence after myomectomy. Br J Obstet Gynaecol 1991;98:385-9. (Level II-3)
31. Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 1995; 10:1795-6. (Level I)
32. Fedele L, Vercellini P, Bianchi S, Brioschi D, Dorta M. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynaecol 1990;97:393-6. (Level I)
33. Malone LJ. Myomectomy: recurrence after removal of solitary and multiple myomas. Obstet Gynecol 1969; 34:200-3. (Level III)
34. Smith DC, Uhlir JK. Myomectomy as a reproductive procedure. Am J Obstet Gynecol 1990;162:1476-9; discussion 1479-82. (Level III)
35. Chong RK, Thong PH, Tan SL, Thong PW, Salmon YM. Myomectomy: indications, results of surgery and relation to fertility. Singapore Med J 1988;29:35-7. (Level III)
36. LaMorte AI, Lalwani S, Diamond MP. Morbidity associated with abdominal myomectomy. Obstet Gynecol 1993;82:897-900. (Level III)
37. Ginsburg ES, Benson CB, Garfield JM, Gleason RE, Friedman AJ. The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study. Fertil Steril 1993;60:956-62. (Level I)
38. Lefebvre G, Vilos G, Allaire C, Jeffrey J, Arneja J, Birch C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003;25:396,418; quiz 419-22. (Level III)
39. Sizzi O, Rossetti A, Malzoni M, Minelli L, La Grotta F, Soranna L, et al. Italian multicenter study on complications of laparoscopic myomectomy. J Minim Invasive Gynecol 2007;14:453-62. (Level II-2)
40. Altgassen C, Kuss S, Berger U, Loning M, Diedrich K, Schneider A. Complications in laparoscopic myomec-tomy. Surg Endosc 2006;20:614-8. (Level II-3)
41. Alessandri F, Lijoi D, Mistrangelo E, Ferrero S, Ragni N. Randomized study of laparoscopic versus minilaparo-tomic myomectomy for uterine myomas. J Minim Invasive Gynecol 2006;13:92-7. (Level I)
42. Palomba S, Zupi E, Falbo A, Russo T, Marconi D, Tolino A, et al. A multicenter randomized, controlled study comparing laparoscopic versus minilaparotomic myomectomy: reproductive outcomes. Fertil Steril 2007;88: 933-41. (Level I)
43. Dubisson JB, Chapron C, Levy J. Difficulties and complications of laparoscopic myomectomy. J Gynecol Surg 1996;12:159-65. (Level III)
44. Seinera P, Arisio R, Decko A, Farina C, Crana F. Laparoscopic myomectomy: indications, surgical technique and complications. Hum Reprod 1997;12: 1927-30. (Level III)
45. Wang CJ, Yuen LT, Lee CL, Kay N, Soong YK. Laparoscopic myomectomy for large uterine fibroids. A comparative study. Surg Endosc 2006;20:1427-30. (Level II-1)
46. Yoo EH, Lee PI, Huh CY, Kim DH, Lee BS, Lee JK, et al. Predictors of leiomyoma recurrence after laparoscopic myomectomy. J Minim Invasive Gynecol 2007; 14: 690-7. (Level II-2)
47. Nezhat FR, Roemisch M, Nezhat CH, Seidman DS, Nezhat CR. Recurrence rate after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 1998;5:237-40. (Level II-3)
48. Advincula AP, Song A, Burke W, Reynolds RK. Preliminary experience with robot-assisted laparoscopic myomectomy. J Am Assoc Gyecol Lapaosc 2004;11: 511-8. (Level III)
49. Wamsteker K, de Blok S, Galilnat A, Lueken RP. Fibroids. In: Lewis BV, Magos AL, editors. Endometrial ablation. New York (NY): Churchill Livingstone; 1992. p.161-81. (Level III)
50. Emanuel MH, Wamsteker K, Hart AA, Metz G, Lammes FB. Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding. Obstet Gynecol 1999;93: 743-8. (Level II-3)
51. Jenkins TR. Hysteroscopic myomectomy: a review. Female Patient 2006;31:37-44. (Level III)
52. Polena V, Mergui JL, Perrot N, Poncelet C, Barranger E, Uzan S. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007;130:232-7. (Level II-2)
53. Pron G, Bennett J, Common A, Wall J, Asch M, Sniderman K. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Ontario Uterine Fibroid Embolization Collaboration Group. Fertil Steril 2003;79:120-7. (Level II-3)
54. Hehenkamp WJ, Volkers NA, Birnie E, Reekers JA, Ankum WM. Pain and return to daily activities after uterine artery embolization and hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial. Cardiovasc Intervent Radiol 2006;29:179-87. (Level I)
55. Hehenkamp WJ, Volkers NA, Donderwinkel PF, de Blok S, Birnie E, Ankum WM, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial): peri- and postprocedural results from a randomized controlled trial. Am J Obstet Gynecol 2005;193:1618-29. (Level I)
56. Goodwin SC, Bradley LD, Lipman JC, Stewart EA, Nosher JL, Sterling KM, et al. Uterine artery embolization versus myomectomy: a multicenter comparative study. Fertil Steril 2006;85:14-21. (Level II-2)
57. Gupta JK, Sinha AS, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005073. DOI: 10.1002/14651858. CD005073.pub2. (Level III)
58. Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002; 100:873-80. (Level III)
59. Broder MS, Goodwin S, Chen G, Tang LJ, Costantino MM, Nguyen MH, et al. Comparison of long-term outcomes of myomectomy and uterine artery embolization. Obstet Gynecol 2002;100:864-8. (Level II-2)
60. Spies JB, Bruno J, Czeyda-Pommersheim F, Magee ST, Ascher SA, Jha RC. Long-term outcome of uterine artery embolization of leiomyomata. Obstet Gynecol 2005;106:933-9. (Level II-3)
61. Mara M, Fucikova Z, Maskova J, Kuzel D, Haakova L. Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2006;126:226-33. (Level I)
62. Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hynyen K, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol 2004;183:1713-9. (Level III)
63. Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids [published erratum appears in Fertil Steril 2006;85:1072]. Fertil Steril 2006;85:22-9. (Level III)
64. Fennessy FM, Tempany CM, McDannold NJ, So MJ, Hesley G, Gostout B, et al. Uterine leiomyomas: MR imaging-guided focused ultrasound surgery - results of different treatment protocols. Radiology 2007;243: 885-93. (Level I)
65. Morita Y, Ito N, Ohashi H. Pregnancy following MR-guided focused ultrasound surgery for a uterine fibroid. Int J Gynaecol Obstet 2007;99:56-7. (Level III)
66. Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007;110:279-87. (Level III)
67. Gerris J, Degueldre M, Peters AA, Romao F, Stjernquist M, al-Taher H. The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group. Horm Res 1996;45:279-84. (Level I)
68. Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995;86:65-71. (Level I)
69. Zullo F, Pellicano M, De Stefano R, Zupi E, Mastrantonio P. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors. Am J Obstet Gynecol 1998;178:108-12. (Level I)
70. Flierman PA, Oberye JJ, van der Hulst VP, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG 2005;112: 638-42. (Level III)
71. Frederick J, Fletcher H, Simeon D, Mullings A, Hardie M. Intramyometrial vasopressin as a haemostatic agent during myomectomy. Br J Obstet Gynaecol 1994;101: 435-7. (Level I-2)
72. Fletcher H, Frederick J, Hardie M, Simeon D. A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy. Obstet Gynecol 1996;87:1014-8. (Level II-1)
73. Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS, Khapra A, Ross PL. The effect of dilute vasopressin solution on blood loss during operative hysteroscopy: a randomized controlled trial. Obstet Gynecol 1996;88:761-6. (Level I)
74. Garnet JD. Uterine rupture during pregnancy. An analysis of 133 patients. Obstet Gynecol 1964;23:898-905. (Level III)
75. Paul PG, Koshy AK, Thomas T. Pregnancy outcomes following laparoscopic myomectomy and single-layer myometrial closure. Hum Reprod 2006;21:3278-81. (Level III)
76. Seracchioli R, Rossi S, Govoni F, Rossi E, Venturoli S, Bulletti C, et al. Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: a randomized comparison with abdominal myomectomy. Hum Reprod 2000;15:2663-8. (Level I)
77. Kumakiri J, Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Itoh S, et al. Pregnancy and delivery after laparoscopic myomectomy. J Minim Invasive Gynecol 2005;12: 241-6. (Level II-2)
78. Parker WH, Iacampo K, Long T. Uterine rupture after laparoscopic removal of a pedunculated myoma. J Minim Invasive Gynecol 2007;14:362-4. (Level III)
79. Banas T, Klimek M, Fugiel A, Skotniczny K. Spontaneous uterine rupture at 35 weeks' gestation, 3 years after laparoscopic myomectomy, without signs of fetal distress. J Obstet Gynaecol Res 2005;31:527-30. (Level III)
80. Grande N, Catalano GF, Ferrari S, Marana R. Spontaneous uterine rupture at 27 weeks of pregnancy after laparoscopic myomectomy. J Minim Invasive Gynecol 2005;12:301. (Level III)
81. Golan D, Aharoni A, Gonen R, Boss Y, Sharf M. Early spontaneous rupture of the post myomectomy gravid uterus. Int J Gynaecol Obstet 1990;31:167-70. (Level III)
82. Ozeren M, Ulusoy M, Uyanik E. First-trimester spontaneous uterine rupture after traditional myomectomy: case report. Isr J Med Sci 1997;33:752-3. (Level III)
83. Hart R, Molnar BG, Magos A. Long term follow up of hysteroscopic myomectomy assessed by survival analysis. Br J Obstet Gynaecol 1999;106:700-5. (Level II-3)
84. Abbas A, Irvine LM. Uterine rupture during labour after hysteroscopic myomectomy. Gynaecol Endosc 1997;6: 245-6. (Level III)
85. Yaron Y, Shenhav M, Jaffa AJ, Lessing JB, Peyser MR. Uterine rupture at 33 weeks' gestation subsequent to hysteroscopic uterine perforation. Am J Obstet Gynecol 1994;170:786-7. (Level III)
86. Manyonda I, Sinthamoney E, Belli AM. Controversies and challenges in the modern management of uterine fibroids. BJOG 2004;111:95-102. (Level III)
87. Olufowobi O, Sharif K, Papaionnou S, Neelakantan D, Mohammed H, Afnan M. Are the anticipated benefits of myomectomy achieved in women of reproductive age? A 5-year review of the results at a UK tertiary hospital. J Obstet Gynaecol 2004;24:434-40. (Level III)
88. Garcia CR, Tureck RW. Submucosal leiomyomas and infertility. Fertil Steril 1984;42:16-9. (Level III)
89. Rice JP, Kay HH, Mahony BS. The clinical significance of uterine leiomyomas in pregnancy. Am J Obstet Gynecol 1989;160:1212-6. (Level II-3)
90. Pritts EA. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 2001;56:483-91. (Level I)
91. Babaknia A, Rock JA, Jones HW Jr. Pregnancy success following abdominal myomectomy for infertility. Fertil Steril 1978;30:644-7. (Level III)
92. Gehlbach DL, Sousa RC, Carpenter SE, Rock JA. Abdominal myomectomy in the treatment of infertility. Int J Gynaecol Obstet 1993;40:45-50. (Level III)
93. Sudik R, Husch K, Steller J, Daume E. Fertility and pregnancy outcome after myomectomy in sterility patients. Eur J Obstet Gynecol Reprod Biol 1996;65:209-14. (Level II-2)
94. Ubaldi F, Tournaye H, Camus M, Van der Pas H, Gepts E, Devroey P. Fertility after hysteroscopic myomectomy. Hum Reprod Update 1995;1:81-90. (Level III)
95. Dubuisson JB, Fauconnier A, Chapron C, Kreiker G, Norgaard C. Reproductive outcome after laparoscopic myomectomy in infertile women. J Reprod Med 2000; 45:23-30. (Level III)
96. Campo S, Campo V, Gambadauro P. Reproductive outcome before and after laparoscopic or abdominal myomectomy for subserous or intramural myomas. Eur J Obstet Gynecol Reprod Biol 2003;110:215-9. (Level II-3)
97. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002; 17:1424-30. (Level III)
98. Surrey ES, Lietz AK, Schoolcraft WB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome. Fertil Steril 2001;75:405-10. (Level II-2)
99. Rackow BW, Arici A. Fibroids and in-vitro fertilization: which comes first? Curr Opin Obstet Gynecol 2005; 17:225-31. (Level III)
100. Tulandi T, Murray C, Guralnick M. Adhesion formation and reproductive outcome after myomectomy and second-look laparoscopy. Obstet Gynecol 1993;82:213-5. (Level III)
101. Dutton S, Hirst A, McPherson K, Nicholson T, Maresh M. A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy. BJOG 2007;114:1340-51. (Level II-2)
102. Ravina JH, Vigneron NC, Aymard A, Le Dref O, Merland JJ. Pregnancy after embolization of uterine myoma: report of 12 cases. Fertil Steril 2000;73:1241-3. (Level III)
103. Hehenkamp WJ, Volkers NA, Brokemans FJ, de Jong FH, Themmen AP, Birnie E, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007;22: 1996-2005. (Level I)
104. Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vanderburgh L, et al. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005;105:67-76. (Level II-3)
105. Rabinovici J, Inbar Y, Eylon SC, Schiff E, Hananel A, Freundlich D. Pregnancy and live birth after focused ultrasound surgery for symptomatic focal adenomyosis: a case report. Hum Reprod 2006;21:1255-9. (Level III)
106. Gavrilova-Jordan LP, Rose CH, Traynor KD, Brost BC, Gostout BS. Successful term pregnancy following MR-guided focused ultrasound treatment of uterine leiomyoma. J Perinatol 2007;27:59-61. (Level III)
107. Hanstede MM, Tempany CM, Stewart EA. Focused ultrasound surgery of intramural leiomyomas may facilitate fertility: a case report. Fertil Steril 2007;88: 497.e5-7. (Level III)
108. Akkad AA, Habiba MA, Ismail N, Abrams K, al-Azzawi F. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1995;86:330-4. (Level II-2)
109. Sener AB, Seckin NC, Ozmen S, Gokmen O, Dogu N, Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996;65:354-7. (Level I)
110. Seltzer V. Screening for ovarian cancer: An overview of the screening recommendations of the 1994 NIH Consensus Conference. Prim Care Update Ob Gyns 1995;2:132-4. (Level III)
111. Reiter RC, Wagner PL, Gambone JC. Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. Obstet Gynecol 1992;79:481-4. (Level III)
112. Piscitelli JT, Simel DL, Addison WA. Who should have intravenous pyelograms before hysterectomy for benign disease? Obstet Gynecol 1987;69:541-5. (Level III)
113. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414-8. (Level III)
114. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006;107:917-21. (Level III)
115. Schwartz LB, Diamond MP, Schwartz PE. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 1993;168:180-3. (Level III)
116. Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 2002; 12:354-61. (Level II-1)
117. Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging 2004;20:998-1007. (Level III)